Pyk2 phosphorylation by her3 induces tumor invasion
OwnerAxel Ullrich, Edward Htun van der Horstinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerAxel Ullrich, Edward Htun van der Horstinventors
Estimating the term…
The present invention relates to the use of a HER2 protein or a nucleic acid coding therefor as a target for the modulation of the mitogen-activated protein (MAP) kinase pathway. Further, the use of a PYK2 protein and a nucleic acid coding therefor as a target for the modulation of the MAP kinase pathway is described. By inhibiting HER3 kinase activity, the phosphorylation of PYK2 and thus the stimulation of the MAP kinase pathway is inhibited. The present invention is preferably suitable for applications, particularly diagnostic or medical applications, wherein an inhibition of the MAP kinase pathway is desired. Thus, the invention relates to novel methods for diagnosing, treating or preventing MAP kinase associated disorders such as tumors.
Use of a HER3 protein as a target for the modulation of the mitogen-activated protein (MAP) kinase pathway.
Use of a nucleic acid encoding a HER3 protein or a nucleic acid complementary thereto as a target for the modulation of the MAP kinase pathway.
Use of a PYK2 protein as a target for the modulation of the MAP kinase pathway.
Use of a nucleic acid encoding an PYK2 protein or a nucleic acid complementary thereto as a target for the modulation of the MAP kinase pathway.
A method of identifying novel modulators of MAP kinase activity comprising screening for substances capable of inhibiting HER3 phosphorylation and/or HER3 kinase activity.
A method of identifying novel modulators of MAP kinase activity comprising screening for substances capable of inhibiting PYK2 phosphorylation and/or PYK2 kinase activity.
Dependencies are inferred from the claim text.